CD8A and neoplasm: Despite contributions by other immune cell subsets, CD8+ T cells have emerged as a predominant effector in most cancer immunotherapy settings, and many immunotherapeutic strategies are devoted to stimulating, enhancing, and maintaining responses by tumor-reactive CD8+ T cells [32].